Core Viewpoint - The establishment of the Medical Artificial Intelligence (AI) Special Committee aims to enhance collaboration and innovation in the field of medical AI and domestic production in China [1] Group 1: Committee Formation - The Medical AI Special Committee was officially established during a seminar in Kunshan, Suzhou [1] - The committee will gather ecological partners to create a robust cooperation platform for medical localization and AI innovation [1] Group 2: Expert Involvement - The first batch of 36 authoritative experts in medical information technology from major hospitals and medical institutions across the country have been appointed [1] - Certificates were awarded to 23 member units, including companies like Weining Health, Donghua Medical, Chuangye Huikang, and Zhiyue Software [1] Group 3: Innovation and Collaboration - The committee aims to promote the entire process of innovation in medical AI, from technology research and development to clinical application [1] - An open platform for cross-industry integration and collaborative development will be established to drive the "photosynthesis" of medical AI innovation [1]

Core Viewpoint - The stock of Chuangye Huikang (300451) has experienced a decline, with significant net outflows from major funds, indicating potential concerns about its financial performance and market sentiment [1][2]. Financial Performance - As of September 18, 2025, Chuangye Huikang's stock closed at 5.03 yuan, down 1.95%, with a trading volume of 477,800 hands and a turnover of 243 million yuan [1]. - The company reported a total revenue of 577 million yuan for the first half of 2025, a year-on-year decrease of 20.65%, and a net profit attributable to shareholders of -80.55 million yuan, a decline of 394.25% [3]. - The second quarter of 2025 saw a single-quarter revenue of 286 million yuan, down 18.48%, and a net profit of -64.91 million yuan, a decrease of 532.25% [3]. Market Position - Chuangye Huikang's total market capitalization is 7.792 billion yuan, with a net asset value of 4.407 billion yuan, and a net profit margin of -12.54% [3]. - The company ranks 82nd in total market value and 166th in net profit within the software development industry [3]. Investment Sentiment - In the last 90 days, three institutions have given buy ratings for Chuangye Huikang, with an average target price of 6.37 yuan [4]. - On September 18, 2025, the net outflow of major funds was 13.38 million yuan, accounting for 5.51% of the total turnover, while retail investors saw a net inflow of 7.57 million yuan, representing 3.12% of the total turnover [1][2].

Group 1 - The Ministry of Commerce and nine other departments have released policies to expand service consumption, focusing on easing market access in high-end medical and leisure vacation sectors to attract foreign and private investment [1] - The initiative aims to increase the supply of quality services and cultivate international markets in healthcare and exhibitions [1] - Analysts suggest that the expansion of the medical sector will create significant business opportunities in medical information technology and smart healthcare services [1] Group 2 - Companies such as Chuangshi Huikang and Langma Information are identified as relevant concepts in the A-share market related to the new policies [1]

Core Viewpoint - The company is transitioning from a traditional IT product supplier to a cloud ecosystem enterprise that provides intelligent medical data services, driven by the need for efficiency in the healthcare industry [1][2]. Industry Transformation - The healthcare information industry is shifting from "system construction" to "data-driven value creation," focusing on long-term cloud services, data value extraction, and open ecosystem collaboration [2]. - The company has established a data-first advantage by forming strategic partnerships and accumulating extensive medical data, including over 1 million structured medical terms and relationships [2]. Product Development and Market Response - The company has developed the Hi-HIS management information system, which has seen a 200% increase in project deliveries in the first half of the year, with significant deployments in various regions [3]. - The MedCopilot intelligent assistant, built on the BsoftGPT model, significantly reduces documentation time and improves efficiency in clinical settings [4]. Technological Collaboration - The company is addressing challenges in computational power and high-quality medical data by collaborating with major tech firms and academic institutions to create a dynamic AI dataset [5][6]. - A joint laboratory with Zhejiang University aims to convert cutting-edge AI technologies into practical solutions for clinical problems, enhancing the synergy between research and application [6]. Future Aspirations - The company aims to deepen the integration of AI with clinical practices, enhance the value of medical data, and promote equitable healthcare through technology [7]. - The management emphasizes a structured talent development approach, ensuring a smooth transition of leadership and responsibilities across generations [7].

Core Insights - The company is transitioning from a traditional IT product supplier to a cloud ecosystem enterprise that provides intelligent medical data services, driven by the pain points in the medical business [1][2] - The healthcare information industry is shifting from "system construction" to "data-driven value creation," focusing on continuous cloud services, data value extraction, and open ecosystem collaboration [2][4] Company Strategy - The company has established a data-first advantage by forming strategic partnerships, such as with Zhejiang University, to create a medical knowledge base that supports AI applications [2][5] - The company has delivered over 20,000 healthcare information projects and managed approximately 300 million resident health records, showcasing its extensive experience in the field [2][3] AI Integration - The company has developed the MedCopilot intelligent assistant, which significantly reduces the time for generating discharge summaries and improves efficiency in medical quality control [4][5] - The company is expanding its AI capabilities across various healthcare scenarios, including internet hospitals, nursing management, and public health services [4][6] Collaborative Efforts - A partnership with Zhejiang University has led to the establishment of a joint laboratory focused on transforming cutting-edge AI technology into practical clinical solutions [5][6] - The collaboration aims to integrate user needs directly into the research and development process, creating a robust innovation engine [6] Future Vision - The company aims to deepen the integration of AI with clinical practices, enhance the value of medical data, and promote equitable healthcare through technology [7] - The management emphasizes a structured approach to talent development, ensuring a smooth transition of leadership and responsibilities across generations [7]

Core Insights - The company is transitioning from a traditional IT product supplier to a cloud ecosystem enterprise that provides intelligent medical data services, driven by the need for efficiency in the healthcare industry [1][4] Industry Transformation - The healthcare information industry is shifting from "system construction" to "data-driven value creation," focusing on long-term cloud services, data value extraction, and open ecosystem collaboration [1][2] - The company has signed strategic cooperation agreements with nearly 500 hospitals and government departments since 2018, implementing over 20,000 healthcare information projects and managing approximately 300 million resident health records [2] AI Integration - The company has developed the MedCopilot intelligent assistant, which significantly reduces the time required for clinical documentation and improves efficiency in medical quality control [2][3] - The company has created over 50 intelligent scenarios covering the entire healthcare information chain, leveraging its self-developed BsoftGPT model [3] Collaborative Innovation - A partnership with Zhejiang University has led to the establishment of a joint laboratory focused on transforming cutting-edge AI technology into practical clinical solutions, combining academic support with real-world application [3] Future Vision - The company aims to deepen the integration of AI with clinical practices, enhance the value of medical data, and promote equitable healthcare through technology [5]

Core Viewpoint - The stock of Chuangye Huikang (300451) has shown fluctuations in trading volume and capital flow, with a notable decline in revenue and profit in the recent financial report, indicating potential challenges ahead for the company [1][3]. Group 1: Stock Performance - As of September 11, 2025, Chuangye Huikang closed at 5.1 yuan, up 0.79%, with a turnover rate of 2.89% and a trading volume of 441,800 hands, amounting to a transaction value of 222.3 million yuan [1]. - The net outflow of main funds on September 11 was 10.63 million yuan, accounting for 4.76% of the total transaction value, while retail investors saw a net inflow of 9.43 million yuan, representing 4.23% of the total [1][2]. Group 2: Financial Performance - For the first half of 2025, Chuangye Huikang reported a main revenue of 577 million yuan, a year-on-year decrease of 20.65%, and a net profit attributable to shareholders of -80.55 million yuan, down 394.25% [3]. - The company's second-quarter results showed a main revenue of 286 million yuan, a decline of 18.48%, and a net profit of -64.91 million yuan, a drop of 532.25% [3]. - The company has a total market value of 7.901 billion yuan, with a net asset of 4.407 billion yuan, and a net profit margin of -12.54% [3]. Group 3: Industry Comparison - Chuangye Huikang's price-to-earnings ratio is -49.04, compared to the software development industry average of 79.58, indicating a significant disparity in profitability metrics [3]. - The company's gross margin stands at 51.45%, which is higher than the industry average of 44.49%, suggesting better cost management in terms of production [3]. Group 4: Analyst Ratings - In the last 90 days, three institutions have given buy ratings for Chuangye Huikang, with an average target price of 6.37 yuan [4].

Core Viewpoint - Philips (China) Investment Co., Ltd. reduced its stake in Chuangye Huikang by selling 560,500 shares, which represents 0.036292% of the total share capital after excluding shares in the repurchase account, bringing its ownership down from 10.036288% to 9.999996% [1] Summary by Relevant Sections - Shareholding Change - Philips (China) Investment Co., Ltd. sold 560,500 shares of Chuangye Huikang [1] - The reduction in shareholding is consistent with previously disclosed plans and has not been fully executed [1] - Impact on Company Control - The share reduction will not lead to a change in the control of the company [1] - The governance structure and ongoing operations of the company remain unaffected [1]

Core Viewpoint - Philips (China) Investment Co., Ltd., a shareholder holding more than 5%, has initiated a share reduction plan for Chuangye Huikang Technology Co., Ltd. [1] Group 1 - On September 9, Philips reduced its holdings by 560,500 shares, representing 0.036292% of the total share capital after excluding shares in the company's repurchase account [1] - Following this equity change, Philips' shareholding has decreased to 9.999996%, falling below the 10% threshold [1] - The company does not have a controlling shareholder or actual controller, and this change will not affect the company's control, governance structure, or ongoing operations [1] Group 2 - Philips has not yet completed its pre-disclosed share reduction plan and will continue to disclose progress [1]

创业慧康科技股份有限公司 上市地点：深圳证券交易所 股票简称：创业慧康 股票代码：300451 信息披露义务人声明 本部分所述词语或简称与本报告书"释义"所述词语或简称具有相同含义。 一、本报告书系依据《中华人民共和国证券法》、《上市公司收购管理办法》 和《公开发行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》 等法律、法规及规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之冲突。 简式权益变动报告书 上市公司：创业慧康科技股份有限公司 信息披露义务人：飞利浦（中国）投资有限公司 住所：上海市静安区灵石路 718 号 A1 幢 通讯地址：上海市静安区灵石路 718 号 A1 幢 股份变动性质：股份减少 签署日期：2025 年 9 月 10 日 1 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》和《公开发 行证券的公司信息披露内容与格式准则第 15 号——权益变动报告书》的规定， 本报告书已全面披露信息披露义务人在创业慧康拥有权益的股份变动情况。截至 本报告书签署日，除本报告书披露的信息外，信息披 ...